CN-121975980-A - Biomarker for diagnosing respiratory syncytial virus and application thereof

Abstract

The invention discloses a biomarker for diagnosing respiratory syncytial virus and application thereof, belonging to the technical field of molecular biology and medical diagnosis. The biomarker LNCRNA SRGAP-AS 1 is obviously related to the RSV infection state, LNCRNA SRGAP-AS 1 presents stable differential expression characteristics under the RSV infection condition, LNCRNA SRGAP-AS 1 can interact with the RNA binding protein PTBP1, has specificity with the expression change of the RSV infection related molecules and the expression change of the epithelial-mesenchymal transition (EMT) related markers, and LNCRNA SRGAP-AS 1 can accurately and specifically detect and assist diagnosis of the RSV infection.

Inventors

• LIU DAISHUN
• WANG SHENGPENG
• WU XIAO
• TAN XINRAN
• LIU YI

Assignees

• 贵州省人民医院

Dates

Publication Date

20260505

Application Date

20260212

Claims (8)

1. 1. A biomarker for diagnosing respiratory syncytial virus is characterized in that the biomarker is an lncRNA molecule.
2. 2. The biomarker for diagnosing respiratory syncytial virus AS claimed in claim 1, wherein the lncRNA molecule is SRGAP2-AS1.
3. 3. Use of a biomarker for diagnosing respiratory syncytial virus according to claim 1 or 2 for the preparation of a product for detecting or diagnosing respiratory syncytial virus.
4. 4. The method of claim 3, wherein the product is a detection reagent or a kit.
5. 5. The method of claim 4, wherein the detection reagent or kit is used for detecting the expression level of SRGAP2-AS1 in the biological sample.
6. 6. The method of claim 4, wherein the level of SRGAP2-AS1 expression in the test agent or kit is positively correlated with the extent of infection by respiratory syncytial virus.
7. 7. The method according to claim 5, wherein the biological sample is selected from the group consisting of oral secretions, serum, alveolar lavage.
8. 8. The method according to claim 4, wherein the detection reagent or kit is used for detecting, aiding diagnosis or evaluating the infection status of respiratory syncytial virus.

Description

Biomarker for diagnosing respiratory syncytial virus and application thereof Technical Field The invention relates to the technical field of molecular biology and medical diagnosis, in particular to a biomarker for diagnosing respiratory syncytial virus and application thereof. In particular to the application of long-chain non-coding RNA (long noncoding RNA, lncRNA) as respiratory syncytial virus (Respiratory Syncytial Virus, RSV) infection in early diagnosis. Background Long non-coding RNA (lncRNA) refers to a class of RNA molecules that are greater than 200 nucleotides in length and do not have or only have limited protein coding capability. Studies have shown that the number and type of lncRNA in the genome is significantly greater than protein-encoding mRNA, but lncRNA, whose biological function has been clarified to date, is still relatively limited. Both human gene-encoded lncRNAs and virus-encoded lncRNAs regulate expression of host genes that may be involved in important processes such as viral replication, latency, activation of signaling pathways, and the like. Currently, there is increasing evidence that lncRNA plays an important role in a variety of biological processes. Respiratory syncytial virus (Respiratory Syncytial Virus, RSV) is an important cause of human respiratory infections, a single-stranded negative-sense RNA virus of the genus pneumovirus, and one of the most common causes of severe pulmonary infectious diseases in infants, elderly and immunocompromised individuals worldwide. In clinic, serum immunization is generally adopted for detection, respiratory syncytial virus detection is used for diagnosing recent respiratory syncytial virus infection, and nucleic acid detection can be used for rapidly diagnosing virus infection. Because of the lack of specificity of early clinical symptoms of RSV infection, the rapid detection of nucleic acids in the prior art has a poor ability to identify early Respiratory Syncytial Virus (RSV) infection. Therefore, the early recognition and accurate diagnosis of RSV infection are realized, and the method has important significance for preventing the disease from further aggravating and developing severe lower respiratory tract infection. Disclosure of Invention Aiming at the defect that the prior art lacks a stable and specific molecular marker which can be used for early recognition and auxiliary diagnosis of Respiratory Syncytial Virus (RSV) infection, the invention provides a biomarker for diagnosing respiratory syncytial virus and application thereof, and mainly improves detection accuracy and clinical application value of RSV infection. In order to achieve the above object, the present invention is achieved by the following technical scheme: it is a first object of the present invention to provide a biomarker for diagnosing respiratory syncytial virus, which biomarker is a lncRNA molecule. lncRNA refers to long non-coding RNAs, i.e., a class of RNA molecules greater than 200 nucleotides in length that do not have or have only limited protein coding capacity. Further, the lncRNA molecules are mainly SRGAP2-AS1. The SRGAP2-AS1 can interact with the RNA binding protein PTBP1 and has correlation with the expression change of the RSV infection related molecule and the expression change of an epithelial-mesenchymal transition (EMT) related marker. The second object of the invention is to provide an application of the biomarker LNCRNA SRGAP-AS 1 in preparing respiratory syncytial virus products for detection or diagnosis. Further, the product is a detection reagent or a kit. Further, the detection reagent or kit detects the expression level of SRGAP2-AS1 in the biological sample. Furthermore, the expression level of LNCRNA SRGAP-AS 1 in the biological sample is positively correlated with the infection degree or detection of respiratory syncytial virus. Further, the biological sample is selected from the group consisting of oral secretions, serum, alveolar lavage, wherein the oral secretions include sputum and pharyngeal swabs, and the serum includes peripheral blood. Further, the product, i.e., the detection reagent or kit, is used for detection, auxiliary diagnosis or infection status assessment of respiratory syncytial virus infection. The biomarker for diagnosing respiratory syncytial virus and the application thereof have the beneficial effects that: (1) The biomarker LNCRNA SRGAP-AS 1 is obviously related to the RSV infection state, LNCRNA SRGAP-AS 1 presents stable differential expression characteristics under the RSV infection condition, LNCRNA SRGAP-AS 1 can interact with the RNA binding protein PTBP1, has specificity with the expression change of the RSV infection related molecules and the expression change of the epithelial-mesenchymal transition (EMT) related markers, and LNCRNA SRGAP-AS 1 can accurately and specifically detect and assist diagnosis of the RSV infection. (2) The invention uses LNCRNA SRGAP-AS 1 AS a biomarker of RSV infectio